Pfizer said on Monday a combination of its breast cancer drug, Ibrance, and another drug was not statistically significant in extending overall survival in certain patients, the secondary goal of a late-stage trial.
Ibrance is Pfizer’s blockbuster treatment and is already approved as a combination with endocrine therapy for use in breast cancer patients. The treatment brought in sales of $933 million in the first quarter of 2018.
Pfizer said on Monday the results demonstrated a positive trend in a ratio that helps determine to what extent a treatment can shorten the duration of an illness, but failed to reach statistical significance.
The company would present detailed data on the trial at an upcoming meeting.
(Source: Reuters)
Filed Under: Drug Discovery
